Compare ADMA Biologics Inc (ADMA) vs Redwire Corporation (RDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Redwire Corporation — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Redwire Corporation trades at $10.38 (market cap $2.03B). The key difference: ADMA Biologics Inc and Redwire Corporation are close in size by market cap, and Redwire Corporation is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | RDW | |
|---|---|---|
Market Cap | $2.13B | $2.03B |
Sector | Health | Technology |
52-Week High | $20.38 | $25.90 |
52-Week Low | $7.60 | $5.06 |
Enterprise Value | $2.20B | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
RDW trades at $11.36, up 0.44% on the day, amid a bearish technical trend and weak fundamentals. The company reported a net loss of $226.55M in 2025 with a -80.9% net income margin, though revenue grew to $335.38M. Recent news highlights volatility driven by SpaceX's IPO impact and a new defense contract, while analyst consensus remains bullish with an $19.00 price target.
The outlook is challenged by persistent losses and cash burn, but strong analyst buy ratings and contract wins offer potential upside. Key risks include dilution from equity offerings, intense space sector competition, and reliance on financing to fund operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
